TICKERNERD
Menu
HOWLHOWLHealthcare · Biotechnology

HOWL Stock Forecast: Werewolf Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.87
+102.67% on the day

The 1 Wall Street analysts covering Werewolf Therapeutics, Inc. hold a median 12-month price target of $7 — +701.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$42.6M
Ticker Nerd rank
80 / 100
Median analyst target
$7.00
Analysts covering
1
Total return, dividends reinvested
1W
+115.7%
1M
+140.6%
YTD
+37.8%
1Y
−31.8%
From 52W high
−60.1%
From 52W low
+183.6%
$0.31
$2.19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HOWL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Werewolf Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
83
Accruals
79
Issuance
78
Value
69
Quality
51
Revisions
47
Volatility
45
Momentum
29

Growth (86): Sales and profits are climbing, and climbing faster than before.

Momentum (29): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HOWL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HOWL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Oct 25Jan 26Apr 26Jul 26HOWLHigh $7.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $7.00Median $7.00High $7.00

The green dot is the last close — the median target sits +701.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Dec 2025HC Wainwright & Co.MaintainsBuy$10 → $4.00
18 Nov 2025B of A SecuritiesMaintainsBuy—
25 Aug 2025B of A SecuritiesMaintainsBuy—
21 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
9 May 2025WedbushMaintainsOutperform—
12 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025WedbushReiteratesOutperform—
14 Jan 2025JMP SecuritiesMaintainsMarket Outperform—
19 Nov 2024HC Wainwright & Co.ReiteratesBuy—
2 July 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024HC Wainwright & Co.ReiteratesBuy—
26 June 2024JMP SecuritiesReiteratesMarket Outperform—
4 June 2024JMP SecuritiesReiteratesMarket Outperform—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
24 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024JMP SecuritiesReiteratesMarket Outperform—
3 Apr 2024JMP SecuritiesInitiatesMarket Outperform—
7 Mar 2024HC Wainwright & Co.MaintainsBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HOWL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

HOWL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Werewolf Therapeutics, Inc. (HOWL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
2.0×

Cheaper than 53% of US stocks

Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
0.0×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
40.7%

Higher than 92% of US stocks

Net margin
−164.8%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−119.9%

Higher than 11% of US stocks

Return on assets
−27.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HOWL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HOWLWerewolf Therapeutics, Inc.$42.6M
80
EDSAEdesa Biotech, Inc.$42.7M
58
TVGNTevogen, Inc.$43.3M
15
ALGSAligos Therapeutics, Inc.$41.3M
75
MCRBSeres Therapeutics, Inc.$43.7M
50
KPTIKaryopharm Therapeutics, Inc.$44.2M
65
VERUVeru, Inc.$45.0M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Werewolf Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HOWL news & analysis

HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 23 Aug 2026negative

Investor rights law firm Halper Sadeh LLC is investigating Werewolf Therapeutics' proposed merger with Ambros Therapeutics to assess whether Werewolf shareholders will receive a fair price. Under the deal, Werewolf shareholders are expected to own approximately 6.8% of the combined company, and the firm is encouraging shareholders to learn about their rights and options.

Why it matters — A HOWL watcher would care because an investor rights law firm is scrutinizing the fairness of the merger terms for Werewolf shareholders ahead of the transaction's closing.

Why Werewolf Therapeutics stock exploded higher and what comes next?

Invezz · 21 Aug 2026positive

Werewolf Therapeutics shares rose sharply after the company announced a definitive all-stock merger with Ambros Therapeutics. The combined company will focus on Ambros' Phase 3 drug candidate neridronate for Complex Regional Pain Syndrome Type 1, supported by an oversubscribed $150 million private placement from institutional investors.

Why it matters — A HOWL watcher would care because the merger marks a major strategic pivot for the company toward a late-stage pain treatment candidate backed by significant institutional funding.

One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story

Benzinga · 21 Aug 2026positive

Werewolf Therapeutics was among the biggest pre-market movers on Friday after announcing a merger with Ambros Therapeutics, a development that a stock-research report described as a $500 million merger story and one of Israel Englander's biotech picks.

Why it matters — HOWL watchers would care because the announced merger with Ambros Therapeutics marks a significant corporate event that drove notable pre-market trading activity in the stock.

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

GlobeNewsWire · 21 Aug 2026neutral

Werewolf Therapeutics and Ambros Therapeutics announced a definitive all-stock merger agreement along with an oversubscribed $150 million private placement. The combined company will focus on Ambros' neridronate program for CRPS-1, operate as Ambros Therapeutics headquartered in San Diego, and is expected to trade under the Nasdaq ticker "AMBX."

Why it matters — A HOWL watcher would care because Werewolf Therapeutics is set to be combined into Ambros Therapeutics, with the merged entity no longer trading under the HOWL ticker.

FAQ

Frequently asked questions about HOWL stock

What is the HOWL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Werewolf Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HOWL stock a buy right now?

Of the 1 analysts covering Werewolf Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Werewolf Therapeutics, Inc. 80 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HOWL?

As at 22 Aug 2026, Werewolf Therapeutics, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will HOWL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +701.4% from the last close, and Ticker Nerd's factor model ranks Werewolf Therapeutics, Inc. 80 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HOWL stock forecast for 2030?

No analyst covering Werewolf Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HOWL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.

How has HOWL stock performed over the past year?

Werewolf Therapeutics, Inc. returned -31.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Werewolf Therapeutics, Inc. do?

Werewolf Therapeutics Inc. is a biopharmaceutical company dedicated to the development of innovative cancer treatments.

What is the latest news on HOWL?

The most recent item we track (Business Wire, 23 Aug 2026): "HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders". Investor rights law firm Halper Sadeh LLC is investigating Werewolf Therapeutics' proposed merger with Ambros Therapeutics to assess whether Werewolf shareholders will receive a fair price. Under the deal, Werewolf shareholders are expected to own approximately 6.8% of the combined company, and the firm is encouraging shareholders to learn about their rights and options.

Company

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics Inc. is a biopharmaceutical company dedicated to the development of innovative cancer treatments. Its primary focus is on pioneering a new wave of immune-therapeutics through the development of conditionally activated biologics, designed to modulate the immune system to selectively target cancer. Werewolf's proprietary platform aims to unleash the full potential of powerful cytokines, which are crucial in immune response, while minimizing systemic toxicity. The company's approach is noteworthy in the industry as it attempts to address the challenging balance between efficacy and safety in cancer therapy. By engineering their molecules to activate precisely within the tumor microenvironment, Werewolf Therapeutics seeks to limit off-target effects, thereby improving patients' quality of care. In the broader financial markets, Werewolf Therapeutics Inc. holds significance as a promising biotech entity involved in cancer immunotherapy, an area that attracts substantial investment interest due to its potential to revolutionize current treatment options. As the market for oncology therapeutics continues to grow, Werewolf stands as a part of the dynamic and evolving landscape of innovative cancer treatment solutions.

CEO Dr. Daniel J. Hicklin Ph.D. · 39 employees · United States · https://werewolftx.com